Anti-digoxin polyclonal antibody

Drug Profile

Anti-digoxin polyclonal antibody

Alternative Names: DIF; DigiBind; DigiFab; Digoxin Immune Fab; Digoxin Immune Fab (Ovine); Polyclonal antibody DigiTAb

Latest Information Update: 05 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Glenveigh Pharmaceuticals; Protherics
  • Developer BTG; Velo Bio
  • Class Antidotes; Polyclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Preeclampsia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Poisoning
  • Phase II/III Preeclampsia

Most Recent Events

  • 01 Jun 2017 AMAG Pharmaceuticals announces intention to submit NDA to the US FDA for Preeclampsia in 2019, with an approval anticipated in 2020
  • 12 Apr 2017 Phase-II/III clinical trials in Preeclampsia in USA (IV)
  • 29 Dec 2016 Velo Bio plans a phase II trial for Preeclampsia in USA (IV, Infusion) (NCT03008616)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top